Top Markets
#1 Black Phoenix Black Phoenix +21,376.82%
#2 Nesa Nesa +748.27%
#3 ADO Protocol ADO Protocol +101.10%
#4 Cortex Cortex +92.95%
#5 Ontology Gas Ontology Gas +65.75%
#6 Kinesis Silver Kinesis Silver +52.89%
#7 OpenEden OpenEden +43.52%
#8 Magma Finance Magma Finance +31.31%
#9 QuantixAI QuantixAI +23.21%
#10 EXOD EXOD +22.78%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Viking Therapeutics, Inc. Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

VKTX
Rank in Stocks #4213
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Share Price
$34.45
Market Cap
$4.02B
Change (1 day)
0.83%
Change (1 year)
32.31%
Country
US
Trade Viking Therapeutics, Inc. (VKTX)

Category

Healthcare
Operating Margin for Viking Therapeutics, Inc. (VKTX)
Operating Margin as of 2026 TTM: 0.00%
According to Viking Therapeutics, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Viking Therapeutics, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.